UMass School of Medicine in Worcester is recruiting teens in Moderna vaccine trial due to start in February

Moderna’s version of COVID-19[female[feminine the vaccine has already been approved for emergency use in people 18 years of age and older. UMass Medical School in Worcester is taking steps to ensure that the vaccine receives the same authorization for adolescents in the United States.

In early February, UMass Medical School will begin enrolling adolescents ages 12 to 17 in clinical trials to test Moderna’s COVID vaccine. It will represent the first tests carried out for a younger population.

Moderna plans to enroll 3,000 teens at 15 sites across the country in the trial called TeenCove, UMass medical school said.

Lead researcher Dr Katerin Luzuriaga, who is the UMass Memorial Health Care Chair in Biomedical Research, said children’s responses to the vaccine may differ from those of adults.

“The objectives of the trial are to assess the safety profile of the vaccine, to see if adolescents have the same level of immune responses as seen in adults and to see if the vaccine protects against disease or infection. “Said Luzuriaga.

Study participants will receive either the vaccine or a placebo in a 2: 1 ratio. People receiving the vaccine will receive two doses of Moderna’s vaccine, 28 days apart – the same guidelines for adults. Participants will be followed for one year after receiving the second dose.

Researchers are trying to recruit teens from across the community, especially underserved racial and ethnic minorities who are most affected by COVID-19.

The study will be conducted at the UMass Center for Clinical and Translational Science Clinical Research Center in the outpatient center on the University campus.

Adolescents and their families can visit for more information.

Related content:

Previous Analysis - As US Cities Adopt Technology, Cyber ​​Attacks Pose Real Risks
Next City of Oswego Forgives COVID-19 Commercial Loans

No Comment

Leave a reply

Your email address will not be published.